Antithrombin Market Overview
Antithrombin is the substance present in the blood. Antithrombin help in limit the bloods ability to coagulate. Antithrombin is the plasma proteins. Antithrombin act as an important regulator in blood coagulation. Antithrombin is the important physiological anticoagulant which inactivates multiple coagulation factors and thrombin. During DIC (disseminated vascular coagulation), antithrombin strongly inhibits the over-activation of coagulation system. Antithrombin is approved by FDA as an anticoagulant before or during surgery for prevention of clots. Antithrombin drugs are low molecular weight heparin (LMWH), unfractionated heparin (UFH), bivalirudin and fondaparinux. Mutations in SERPINC1 gene causes hereditary antithrombin deficiency. Clot-busting drugs are called as thrombolytic drugs which breaks up and dissolves blood clots. Streptase (streptokinase), Eminase (anistreplase), Retavase (reteplase) are the examples of thrombolytic drugs. Tissue plasminogen activator is the common drug used for thrombolytic therapy. Anticoagulants helps in preventing blood clots. Dabigatran (Pradaxa), edoxaban (Lixiana), rivaroxaban (Xarelto) and apixaban (Eliquis) are the examples of anticoagulants. When there is disruption in flow of blood anticoagulants are used. Rise in surgeries has given rise in use of Antithrombin thus resulting in growth of the market.
Antithrombin Market size accounted for US$ 577.2 million in 2020 and is estimated to be US$ 849.87 million by 2030 and is anticipated to register a CAGR of 4.3%.
Antithrombin Market Dynamics
Rise in surgical procedures
Rise in surgical procedure is one of the leading factors for the global antithrombin market growth. Rise in prevalence of disease has led to increase in surgical procedures. DTo ease the paiun and for treatment of diseases the surgical procedures are performed. Increase in chronic diseases like heart, kidney disease has given rise in surgeries. Purpose of surgery is to improve the physical appearance, transplant tissue or whole organs, repairing diseased tissue or organs, to reposition the structure to its normal position. Antithrombin is used before, after and during the surgical procedures which helps in preventing the blood clots. For instance, in 2002, the Antithrombin III concentrate was used to treat the heparin resistance in patients who were undergoing the cardiac surgery. Treatment with Antithrombin III concentrate was resulted in giving potentiality of heparin effect to meet the activated clotting time and thus allowed for cardiac surgery. However, the growth in surgical procedures has boosts the demand for antithrombin market.
Rise in antithrombin deficiency and demand for antithrombin
Rise in antithrombin deficiency and demand for antithrombin has become the major factor in growth of antithrombin market. Deficiencies of anticoagulants and antithrombin gives rise to high risk of thrombophilias. Maintaining adequate levels of antithrombin is very important to prevent high risk thrombophilias. Antithrombin also has excellent anti-inflammatory properties and great affinity for thrombin. Due to its remarkable properties antithrombin are high in demand. Antithrombin is complex molecule with biological properties. For instance, in 2013, the clinical use and Italian demand for antithrombin has increased due to its remarkable properties. For instance, in 2009, use of antithrombin concentrates prothrombin complex concentrates were recommended therapeutically in primary and acquired antithrombin deficiency.
Restrains:
However, risk of blood borne diseases may somewhat restrain the growth of the target market.
Antithrombin Market Segmentation
The antithrombin market is segmented based on type, application, and region.
On the basis of type, the antithrombin market is segmented into Thrombolytic Drugs, Anticoagulant, Antiplatelet and others. On the basis of application, the target market is classified into Therapeutics, Research & Development, Diagnostics, and others.
Regional Insights:
On region the antithrombin market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as India and China, and technological advancements. Moreover, rising presence of industrial corridor and increased incidence of cardiac disease is anticipated to increase demand for antithrombin in the region.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2030 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 to 2030 |
|
Market Segmentation |
By Type - Thrombolytic Drugs, Anticoagulant, Antiplatelet and others By Application – Therapeutics, Research & Development, Diagnostics, and others
|
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global antithrombin market report based on type, application, and region:
Antithrombin Market, By Type:
- Thrombolytic Drugs
- Anticoagulant
- Antiplatelet
- Others
Antithrombin Market, By Application:
- Therapeutics
- Research & Development
- Diagnostics
- Others
Antithrombin Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Antithrombin Market Key Players
The key players operating the antithrombin market includes, Takeda Pharmaceuticals, Siemens AG, Axis-Shield Plc., Grifols, CSL Limited, Thermo Fisher Scientific, Octapharma AG, Lee Biosolutions Inc., Shire Plc., LFB USA, Scripps Laboratories Inc., Kedrion S.p.A., Novartis International AG, Bristol-Myers Squibb Company, Merck & Co, and others. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. For instance, in 2022, Grifols signs the global collaboration agreement with the Endpoint Health to develop and commercialize Antithrombin III for treatment of Sepsis and blood clotting disorder.
Antithrombin Market Company Profile
- Grifols*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Takeda Pharmaceuticals
- Siemens AG
- Axis-Shield Plc.
- CSL Limited
- Thermo Fisher Scientific
- Octapharma AG
- Lee Biosolutions Inc.
- Shire Plc.
- LFB USA
- Scripps Laboratories Inc.
- Kedrion S.p.A.
- Novartis International AG
- Bristol-Myers Squibb Company
- Merck & Co.
“*” marked represents similar segmentation in other categories in the respective section
Antithrombin Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for medical carts Strategies
- Key Questions this Study will Answer
- Market Snippet, By Type
- Market Snippet, By Application
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restrains
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Antithrombin Market, By Type
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Thrombolytic Drugs
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Anticoagulant
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Antiplatelet
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Antithrombin Market, By Application, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Therapeutics
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Research & Development
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Diagnostics
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Antithrombin Market, By Region, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Takeda Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Siemens AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Axis-Shield Plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Grifols
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- CSL Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Thermo Fisher Scientific
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Octapharma AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Lee Biosolutions Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Shire Plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- LFB USA
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Scripps Laboratories Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Kedrion S.p.A.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck & Co.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The Antithrombin Market is segmented into basis of on type, application, and region.
Rise in surgical procedure is one of the leading factors for the antithrombin market growth.
By region, The North America market is estimated to witness a significantly high revenue share over the forecast period.
The Key players operating in the Antithrombin Market includes Takeda Pharmaceuticals, Siemens AG, Axis-Shield Plc., Grifols, CSL Limited, Thermo Fisher Scientific, Octapharma AG, Lee Biosolutions Inc., Shire Plc., LFB USA, Scripps Laboratories Inc., Kedrion S.p.A., Novartis International AG, Bristol-Myers Squibb Company, Merck & Co, and others.